Phase II trial of a telomerase cancer vaccine (TeloB-VAX) in patients with castrate-resistant prostate cancer

Trial Profile

Phase II trial of a telomerase cancer vaccine (TeloB-VAX) in patients with castrate-resistant prostate cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2013

At a glance

  • Drugs TeloB-VAX (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Aug 2013 New trial record
    • 27 Jul 2011 Adamis Pharmaceuticals Corporation received a milestone payment, providing funds to move its prostate cancer vaccine into a phase II study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top